95. Lower estrogen after menopause and increased cardiovascular risk: Hayashi, T. et al. “Effect of Estrogen on Isoforms of Nitric Oxide Synthase: Possible Mechanism of Anti-Atherosclerotic Effect of Estrogen,” Gerontology, 15 April 2009, http://www.karger.com/Article/Abstract/213883.
96. Statins stimulate nitric oxide: Cerda, Alvaro et al. “Role of microRNAs 221/222 on Statin Induced Nitric Oxide Release in Human Endothelial Cells,” Arquivos Brasileiros de Cardiologia, March 2015, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4386847/.
97. Side effects of statins: “Side Effects of Cholesterol-Lowering Statin Drugs,” WebMD, Acessed April 2017, http://www.webmd.com/cholesterol-management/side-effects-of-statin-drugs#1.
98. Statins ineffective with dirty NOS3: Hsu, CP. et al. “Asymmetric Dimethylarginine Limits the Efficacy of Simvastatin Activating Endothelial Nitric Oxide Synthase,” Journal of the American Heart Association, 18 April 2016, https://www.ncbi.nlm.nih.gov/pubmed/27091343.
99. Nitroglycerin resistance: Münzel, T. et al. “Effects of long-term nitroglycerin treatment on endothelial nitric oxide synthase (NOS III) gene expression, NOS III-mediated superoxide production, and vascular NO bioavailability,” Circulation Research, 7 January 2000, https://www.ncbi.nlm.nih.gov/pubmed/10625313.
100. Ineffectiveness of nitroglycerin in smokers: Haramaki, N. et al. “Long-term smoking causes nitroglycerin resistance in platelets by depletion of intraplatelet glutathione,” Arteriosclerosis, Thrombosis, and Vascular Biology, November 2001, https://www.ncbi.nlm.nih.gov/pubmed/11701477.
101. Nitroglycerin and arginine with NOS3: Daiber A., Münzel T. “Organic Nitrate Therapy, Nitrate Tolerance, and Nitrate-Induced Endothelial Dysfunction: Emphasis on Redox Biology and Oxidative Stress,” Antioxidants & Redox Signaling, 10 October 2015, https://www.ncbi.nlm.nih.gov/pubmed/26261901.
102. Arginine steal: Pernow, J., Jung, C. “Arginase as a potential target in the treatment of cardiovascular disease: reversal of arginine steal?” Cardiovascular Research, 1 June 2013, https://www.ncbi.nlm.nih.gov/pubmed/23417041.
103. Bacteria stealing arginine: Cunin, Raymond et al. “Biosynthsis and Metabolism of Arginine in Bacteria,” Microbiological Reviews, September 1986, http://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC373073&blobtype=pdf.
104. Arginine ineffective in increasing nitric oxide: Giam, B. et al, “Effects of Dietary l-Arginine on Nitric Oxide Bioavailability in Obese Normotensive and Obese Hypertensive Subjects,” Nutrients, 14 June 2016, https://www.ncbi.nlm.nih.gov/pubmed/27314383.
105. BH4 given to support NOS3: Vásquez-Vivar, J. et al. “Altered tetrahydrobiopterin metabolism in atherosclerosis: implications for use of oxidized tetrahydrobiopterin analogues and thiol antioxidants,” Arteriosclerosis, Thrombosis, and Vascular Biology, 1 October 2002, https://www.ncbi.nlm.nih.gov/pubmed/12377745.
106. Effectiveness of BH4 given to support NOS3: Mäki-Petäjä, KM. et al. “Tetrahydrobiopterin Supplementation Improves Endothelial Function But Does Not Alter Aortic Stiffness in Patients With Rheumatoid Arthritis,” Journal of the American Heart Association, 19 February 2016, https://www.ncbi.nlm.nih.gov/pubmed/26896473.
107. How the body uses arginine: Förstermann, Ulrich, Sessa, William C. “Nitric oxide synthases: regulation and function,” European Heart Journal, April 2012, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3345541/.
108. Folic acid increases, level of BH4 decreases: Smith, Desirée E.C. et al. “Folic acid, a double-edged sword? Influence of folic acid on intracellular folate and dihydrofolate reductase activity,” Semantic Scholar, Accessed January 2017, https://pdfs.semanticscholar.org/d934/683d6176b469ff636c4e202b8f99f6bb7217.pdf
109. Sleep apnea and NOS3: Badran, Mohammad et al. “Nitric Oxide Bioavailability in Obstructive Sleep Apnea: Interplay of Asymmetric Dimethylarginine and Free Radicals,” Sleep Disorders, 2015, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4438195/.
110. Elevated levels of homocysteine leads to increased levels of ADMA: Selley, ML. “Increased concentrations of homocysteine and asymmetric dimethylarginine and decreased concentrations of nitric oxide in the plasma of patients with Alzheimer’s disease,” Neurobiology of Aging, November 2003, https://www.ncbi.nlm.nih.gov/pubmed/12928048.
111. High ADMA levels found in dementia: Selley, ML. “Increased concentrations of homocysteine and asymmetric dimethylarginine and decreased concentrations of nitric oxide in the plasma of patients with Alzheimer’s disease,” Neurobiology of Aging, November 2003, https://www.ncbi.nlm.nih.gov/pubmed/12928048.
112. Heart disease related death in dementia patients: Brunnström, HR., Englund, EM. “Cause of death in patients with dementia disorders,” European Journal of Neurology, April 2009, https://www.ncbi.nlm.nih.gov/pubmed/19170740.
113. BH4 has no benefit if oxidative stress is present: Kirsch, Michael et al. “The Autoxidation of Tetrahydrobiopterin Revisited,” The Journal of Biological Chemistry, 24 April 2003, http://www.jbc.org/content/278/27/24481.abstract.
114. BH4 has no benefit if oxidative stress is present: Vásquez-Vivar, Jeannette. “Tetrahydrobiopterin, Superoxide and Vascular Dysfunction,” Free Radical Biology and Medicine, 21 July 2009, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2852262/.
11: PEMT: клеточные мембраны и печень
115. Role of phosphatidylcholine: Vance, Dennis E., Li, Zhaoyu, Jacobs, Rene L. “Hepatic Phosphatidylethanolamine N-Methyltransferase, Unexpected Roles in Animal Biochemistry and Physiology,” The Journal of Biological Chemistry, 16 November 2007, http://www.jbc.org/content/282/46/33237.full.pdf.
